These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29173760)

  • 1. Targeting DNA damage in SCLC.
    Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
    Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation.
    Wéra AC; Lobbens A; Stoyanov M; Lucas S; Michiels C
    Cell Cycle; 2019 Aug; 18(15):1770-1783. PubMed ID: 31238782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
    Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
    Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
    Sharp A; Bhosle J; Abdelraouf F; Popat S; O'Brien M; Yap TA
    Eur J Cancer; 2016 Jun; 60():26-39. PubMed ID: 27060747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
    Guo MZ; Marrone KA; Spira A; Scott SC
    Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancer.
    Zhang J; Liu X; Hou P; Lv Y; Li G; Cao G; Wang H; Lin W
    Cell Death Dis; 2024 Jul; 15(7):551. PubMed ID: 39085197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications.
    Wang X; Zeng X; Li D; Zhu C; Guo X; Feng L; Yu Z
    Biomed Pharmacother; 2022 Sep; 153():113458. PubMed ID: 36076571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
    Thomas A; Vilimas R; Trindade C; Erwin-Cohen R; Roper N; Xi L; Krishnasamy V; Levy E; Mammen A; Nichols S; Chen Y; Velcheti V; Yin F; Szabo E; Pommier Y; Steinberg SM; Trepel JB; Raffeld M; Young HA; Khan J; Hewitt S; Lee JM
    J Thorac Oncol; 2019 Aug; 14(8):1447-1457. PubMed ID: 31063862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
    BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
    Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
    Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.